BioVaxys Technology Corp.

Equities

BIOV

CA09076M1014

Biotechnology & Medical Research

Delayed Canadian Securities Exchange Other stock markets 20:35:54 15/05/2024 BST			5-day change	1st Jan Change
0.07 ^CAD	-12.50%		-.--%	+40.00%

07-10	BioVaxys Technology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	CI
07-10	BioVaxys Technology Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024	CI

BioVaxys Technology Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024

July 10, 2024 at 06:29 pm

BioVaxys Technology Corp. reported earnings results for the first quarter ended January 31, 2024. For the first quarter, the company reported net income was CAD 0.518049 million compared to net loss of CAD 0.956045 million a year ago.

Latest news about BioVaxys Technology Corp.

BioVaxys Technology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	07-10	CI
BioVaxys Technology Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024	07-10	CI
BioVaxys Technology Corp. Reports Earnings Results for the Full Year Ended October 31, 2023	07-09	CI
Biovaxys Technology Corp. Delays to File Its Interim Financial Statements for the Three Months Ended January 31, 2024	05-02	CI
BioVaxys Technology Corp. Appoints Christopher Cherry as Chief Financial Officer	04-30	CI
Biovaxys and SpayVac-For-Wildlife, Inc. Announce Launch of Field Trial for Large-Scale Immunocontraception in the Commercial Aquatic Farming Industry	04-10	CI
BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMage	04-03	CI
BioVaxys Technology Plans Private Placement; Down 5.9%	03-25	MT
BioVaxys Technology Corp. announced that it expects to receive CAD 1 million in funding	03-21	CI
Down 17%, BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update	03-07	MT
BioVaxys Technology Corp. Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications	03-05	CI
Biovaxys Completes The Acquisition Of All Intellectual Property And Clinical Stage Assets Of The Former IMV Inc.	02-21	MT
BioVaxys Acquires Entire Technology Portfolio Of The Former IMV Inc.	02-12	MT
BioVaxys Technology Corp. announced that it has received CAD 1.605 million in funding	02-08	CI
BioVaxys Technology Corp. announced that it expects to receive CAD 1.6 million in funding	01-07	CI
BioVaxys Executes Letter of Intent for Major Immunotherapeutics Technology Buy; Comes After BioVaxys and Procare Health Agreed to Terminate USA Distribution Agreement for Papilocare	12-22	MT
BioVaxys and Procare Health Agreed to Terminate USA Distribution Agreement for Papilocare	12-22	MT
BioVaxys Technology Corp. and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare and Immunocaps	12-20	CI
BioVaxys in Non-Binding Discussions for Major Immunotherapeutics Technology Acquisition	12-13	MT
BioVaxys Technology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	11-14	CI
BioVaxys Technology Corp. and The Ohio State University Extend Research Collaboration	28/08/23	CI
BioVaxys Technology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	29/06/23	CI
10402588 BC Ltd acquired TAETSoftware Corp.	12/06/23	CI
Biovaxys Technology Corp. Announces Chief Financial Officer Changes	07/06/23	CI
Biovaxys Technology Corp. Announces Corporate Secretary Changes	07/06/23	CI

Chart BioVaxys Technology Corp.

Duration

Period

More charts

Company Profile

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

Sector

Biotechnology & Medical Research

Calendar

14/08/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOVAXYS TECHNOLOGY CORP.	+40.00%	11.28M
VERTEX PHARMACEUTICALS INCORPORATED	+21.30%	127B
REGENERON PHARMACEUTICALS, INC.	+24.12%	117B
ARGENX SE	+26.26%	27.67B
BIONTECH SE	-18.91%	20.33B
GENMAB A/S	-15.87%	16.79B
BEIGENE, LTD.	-18.38%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+13.57%	14.84B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.97%	14.43B

Bio Therapeutic Drugs